Global Dry Eye Disease Sales Market Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Dry Eye Disease Sales Market Report 2024
Market Analysis and InsightsGlobal Dry Eye Disease Market
Dry eye disease is a multifactorial disease which is characterized by insufficiency of tears in eye. Insufficient lubrication in eye lead to burning, sensing, redness and pain in eye.
Due to the COVID-19 pandemic, the global Dry Eye Disease market size is estimated to be worth US$ 2397.5 million in 2024 and is forecast to a readjusted size of US$ 2949.6 million by 2034 with a CAGR of 2.6% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Artificial Tears accounting for % of the Dry Eye Disease global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospital segment is altered to an % CAGR throughout this forecast period.
The United States Dry Eye Disease market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Dry Eye Disease include Santen Pharma, Novartis, Llergan, Takeda, TRB Chemedica, Sun Pharmaceutical, Senju Pharmaceutical, Sentiss Pharma and Johnson & Johnson, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Dry Eye Disease Scope and Market Size
The global Dry Eye Disease market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Dry Eye Disease market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
Artificial Tears
Anti-inflammatory Drugs
Other
Hospital
Drug Stores
Online Pharmacies
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
Santen Pharma
Novartis
Llergan
Takeda
TRB Chemedica
Sun Pharmaceutical
Senju Pharmaceutical
Sentiss Pharma
Johnson & Johnson
Otsuka
Mitotech
FCI
Altacor
Valeant Pharmaceuticals
United Laboratories
Jianfeng Group
Eusan GMBH
Dry eye disease is a multifactorial disease which is characterized by insufficiency of tears in eye. Insufficient lubrication in eye lead to burning, sensing, redness and pain in eye.
Due to the COVID-19 pandemic, the global Dry Eye Disease market size is estimated to be worth US$ 2397.5 million in 2024 and is forecast to a readjusted size of US$ 2949.6 million by 2034 with a CAGR of 2.6% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Artificial Tears accounting for % of the Dry Eye Disease global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospital segment is altered to an % CAGR throughout this forecast period.
The United States Dry Eye Disease market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Dry Eye Disease include Santen Pharma, Novartis, Llergan, Takeda, TRB Chemedica, Sun Pharmaceutical, Senju Pharmaceutical, Sentiss Pharma and Johnson & Johnson, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Dry Eye Disease Scope and Market Size
The global Dry Eye Disease market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Dry Eye Disease market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
Artificial Tears
Anti-inflammatory Drugs
Other
Segment by Application
Hospital
Drug Stores
Online Pharmacies
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Santen Pharma
Novartis
Llergan
Takeda
TRB Chemedica
Sun Pharmaceutical
Senju Pharmaceutical
Sentiss Pharma
Johnson & Johnson
Otsuka
Mitotech
FCI
Altacor
Valeant Pharmaceuticals
United Laboratories
Jianfeng Group
Eusan GMBH